5-Year Real-World Outcomes With Frontline Pembrolizumab Monotherapy in PD-L1 Expression ≥ 50% Advanced NSCLC
Author:
Vamsidhar Velcheti,Pragya Rai,Yu-Han Kao,Diana Chirovsky,Ana Tablante Nunes,Stephen V. Liu
Publication:
Clinical Lung Cancer
© 2024 Merck Sharp & Dohme LLC., a subsidiary of Merck & Co., Inc., Rahway, NJ, USA. and The Author(s). Published by Elsevier Inc.